Venoruton in venous insufficiency, capsules 300mg, 50pcs

Composition

1 capsule contains:

Active ingredient:

hydroxyethylrutosides 300 mg,

excipients:  

macrogol 6000-9 mg,

empty solid gelatin capsule:

gelatin — about 63.0097 mg;

water-11.02 mg;

titanium dioxide-about 1.5 mg;

iron oxide yellow dye-about 0.47 mg.

The capsule is printed with black ink, the capsule contains trace amounts of ink,

the main ingredients of printing ink:  

shellac in ethanol; iron oxide black dye; n-butanol; propylene glycol; isopropanol; water ammonia

Pharmacological action

The drug has an angioprotective and phlebotonic effect. Derived routine. It acts mainly on capillaries and veins. Reduces the pores between endothelial cells by modifying the fibrous matrix located between endothelial cells. Inhibits aggregation and increases the degree of deformability of red blood cells. It has an anti-inflammatory effect. In chronic venous insufficiency, Venoruton ® reduces the severity of its manifestations such as edema, pain, convulsions, trophic disorders, varicose ulcers. Reduces symptoms associated with hemorrhoids, including pain, itching, and bleeding. Having a beneficial effect on the permeability and resistance of capillary walls, the drug helps to slow down the development of diabetic retinopathy. Due to the effect of rutoside on the rheological properties of blood, the drug helps prevent retinal microthrombosis.

Clinical pharmacology

Absorption and distributionafter oral use, absorption is about 10-15%. Cmax in blood plasma is reached within 1-9 hours. Concentrations remain detectable for 120 h; their decrease occurs biexponentially. Excretion1 / 2 is 10-25 h. O-(β-hydroxyethyl)- rutosides and their glucuronic metabolites are mainly excreted in the bile,3-6% is excreted by the kidneys in 48 hours.

Indications

Chronic venous insufficiency; postphlebitic syndrome;trophic disorders varicose veins;venous ulcers;as an auxiliary treatment for lymphedema after conducting sclerosing therapy and removal of varicose nodes;hemorrhoids (pain, exudation, itching and bleeding);venous insufficiency and hemorrhoids in pregnancy, starting from the second trimester; as auxiliary treatment of retinopathy in patients with diabetes mellitus, hypertension and atherosclerosis.

Use during pregnancy and lactation

Clinical studies have studied the use of Venoruton during pregnancy, but its use in the first trimester has not been specifically studied. Use in the first trimester of pregnancy is contraindicated. In animal studies, no teratogenic or other undesirable effects of the drug on the fetus were observed. It is recommended to prescribe Venoruton® orally only starting from the second trimester of pregnancy, when the expected benefit to the mother from its use exceeds the possible risk to the fetus.

Contraindications

Hypersensitivity to rutosides or other components of the drug; I trimester of pregnancy, children under 18 years of age. Use with caution in patients with hepatic, renal or heart failure.

Side effects

From the digestive system: nausea, diarrhea, heartburn. Allergic reactions: skin rash. Other: headache, flushes of blood to the face. Side effects quickly disappear after discontinuation of the drug.

Interaction

The effect of Venoruton is enhanced when used simultaneously with ascorbic acid.

How to take, course of use and dosage

Inside is prescribed at the beginning of treatment 300 mg (1 capsule) 3 times / day with meals. A reduction in the severity of symptoms is usually noted within 2 weeks of treatment. It is recommended to continue taking the drug at the same dose or reduce it to a minimum maintenance dose of 600 mg / day, or stop treatment. At the same time, the achieved effect persists for 4 weeks. Capsules are swallowed whole, washed down with a sufficient amount of water. For lymphostasis, the recommended dose is 3 g / day. For diabetic retinopathy,0.9-1.8 g/day is prescribed.

Overdose

No cases of overdose with clinical symptoms have been reported.

Description

Capsules are gelatinous, opaque, yellow-beige, odorless, labeled “Venoruton 300”; the contents of the capsules are yellow to brownish-yellow powder, odorless.

Special instructions

If the use of the drug does not reduce the severity of the symptoms of the disease, it is recommended to verify the diagnosis.

Product form

10 pcs. – blisters (5) – cardboard packs.

Storage conditions

The drug should be stored in a dry place, out of reach of children, at a temperature not exceeding 30°C.

Shelf

life is 3 years.

Active ingredient

Rutoside

Dosage form

Capsules

Description

Pregnant women in the second and third trimester as prescribed by a doctor, For adults

Indications

Hemorrhoids, Trophic ulcers, Varicose veins, Atherosclerosis, Vascular lesions in diabetes mellitus